Between 2023 to 2028, the global market for cell line development is predicted to rise at a CAGR of 16.12% and be worth USD 13.70 billion by 2028 from USD 6.87 billion in 2023.
Based on type, the primary cell line segment led the cell line development market in 2022 and is expected to maintain the same pace during the period.
Based on the source, the mammalian segment is projected to have a significant CAGR during the forecast period.
Based on Application, the bioproduction segment dominated the cell line development market in 2022 and is expected to lead during the forecast period.
The North American cell line development market is anticipated to be worth USD 4.14 billion by 2027.
The Asia Pacific American cell line development market is projected to showcase the fastest CAGR of 18.23% during the forecast period.
A cell line is a permanently established cell culture that multiples indefinitely given proper media and space and is frequently used to investigate biological processes in place of primary cells. Cell line development is the process of creating stable cell lines for use in various applications, including the creation of biologics, drug screening, and functional gene investigations. Cell lines are one of the most important research tools for investigating cell physiology and biochemistry, pharmacological and hazardous substance effects on cells, drug screening, and the production of biological compounds. Cell lines, also known as sub-clones, are a subculture of primary culture.
Impact of COVID-19 on the global cell line development market:
The COVID-19 pandemic had a detrimental impact on the healthcare industry, resulting in the closure of many manufacturing sites and a drop in product demand worldwide. Over the forecast period, the increased prevalence of COVID-19 is expected to impact cell line development market growth. The coronavirus outbreak, which has hampered the cell line development market, has caused significant losses for most of the drug industry. However, once global activities resume and government lockdowns in a few nations are lifted, the global market may get some relief over the analysis period. In addition, with more biopharmaceutical companies embracing cell line development techniques, the global market is expected to rise steadily during the forecast period.
Emerging economies and underdeveloped countries are lucrative regional markets for cell line development worldwide, and these countries are anticipated to offer numerous growth possibilities to the market players. The growing usage of regenerative medicine, increasing spending on healthcare, and rising investments in biotechnology are predicted to have a favorable impact on cell line development market growth. Cell culture, drug discovery, and gene therapy are some of the established applications for cell line development in the biotechnology industry. The demand for biosimilars is increasing due to the patent expiry of branded medicine and recombinant proteins, which is projected to result in the cell line development market growth.
In addition, the increasing involvement of several CDMOs in the cell line development market are fuelling the market's growth rate. For instance, AGC Biologics, a leading biopharmaceutical CDMO was named the Leading Innovator in Mammalian Cell Line Development for the USA in 2022, supporting market growth.
Cell line development is a time-consuming and labor-intensive operation, which has lowered its appeal among several companies, resulting in reduced adoption and inhibiting the market growth. Developing stable and authentic cell lines remains a key challenge despite the market's innovative technologies. In the coming years, factors such as misidentification, random alterations, and contamination in cell line development are anticipated to showcase a negative impact on market growth.
Market Size Available
2022 to 2028
2023 to 2028
By Type, Source, Application & Region
Various Analyses Covered
Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities
North America, Europe, Asia Pacific, Latin America, Middle East, and Africa
This research report on the global cell line development market has been segmented and sub-segmented based on type, source, application & region.
Cell Line Development Market – By Type:
Recombinant Cell Lines
Continuous Cell Lines
Primary Cell Lines
Based on type, the primary cell line segment is the fastest-growing segment among all in the worldwide market due to its vast application in genetics, cell morphology, cell metabolism, and physiology. Embryonic, normal, and malignant tissues are used to start cell culture. The recombinant cell lines segment is also expected to witness growth during the forecast period due to the several applications of the cell lines in therapeutical applications for conditions like cancer, diabetes, and even autoimmune disorders. Furthermore, recombinant cell line has applications in gene activations, drug testing, production of biologics, etc., leading to growth for the segment.
Cell Line Development Market – By Source:
Mammalian Cell Line Development
Non-Mammalian Cell Line Development
Over the forecast period, the mammalian segment is expected to grow at the fastest CAGR based on the source. On the other hand, the non-mammalian segment is anticipated to hold a considerable share of the worldwide market during the forecast period. The non-mammalian segment has been experiencing several developments all these years and is yet to be a prominent process. SF-RVN cell line developed by MilliporeSigma was the first ever non-mammalian cell line development.
Cell Line Development Market – By Application:
Drug Discovery and Research
Tissue Engineering & Regenerative Medicine
Due to increased antibiotics and vaccine production, the bioproduction segment accounted for the major share of the global market in 2022. The bioproduction segment includes the production of biologics-based therapeutic pharmaceuticals such as vaccines, therapeutic proteins, cell therapies, and gene therapies. Antibiotics and vaccines are the most prevalent bioproduction products, and segmental growth is expected to rise considerably in the future due to the rise of pandemics and infectious diseases, particularly in developing countries.
However, cell line development has varied applications in drug discovery and research. Cell lines help determine the toxicity and efficacy of a drug. They are beneficial in various research procedures as they are the base material for cell research. For example, cancer cell lines are extensively used in drug discovery and pathological treatment regimes. Cell line therapeutics s also used to produce antibody-based therapeutics supporting the growth of the segment.
Cell Line Development Market – By Region:
Middle East and Africa
Because government and private sector companies are spending more money on healthcare, the Asia Pacific regional market is expected to rise rapidly. As a result, the biotechnology industry in developing economies is expected to increase significantly during the forecast period. Government measures such as public healthcare programs and enhanced healthcare infrastructure are helping the biotechnology sector growth in developing economies. Additionally, the growing research and development in biologics in countries like China, India, Japan, South Korea, etc., are expected to support the market growth. Furthermore, the growing cases of chronic diseases like cancer, diabetes, and cardiovascular diseases requiring the assistance of biologics and drug development support the market growth in the region. Additionally, the growing number of pharmaceuticals and the need for better healthcare infrastructures due to growing geriatric populations are also supporting the advancement of the region.
Due to the presence of constant technological developments followed by discoveries, the North American regional market accounted for the most significant revenue share in the coming years, spurring the adoption of newer bioproduction techniques. In addition, the rigorous activities carried out by research businesses operating in this region, such as Thermo Fisher Scientific Inc., the American Type Culture Collection (ATCC), and Sigma-Aldrich Corporation, which provide high-quality biologics services, are contributing to the expansion. Furthermore, the growing advancements in biopharmaceuticals using several bio-cell services like cell banking and cell line development equipment support the market growth in the region. As cell line development is an essential requirement for various research and development procedures, there is high demand for the market with growing advancements in biologics and gene investigations. Additionally, the stringent FDA approvals for clinical R&D support the market growth in the region. Therefore, countries like the U.S. and Canada are expected to contribute significantly to the market.
KEY MARKET PARTICIPANTS:
Merck KGaA, Selexis SA, Lonza, ATCC, Solentim Ltd., Sphere Fluidics Limited, WuXi Biologics, Thermo Fisher Scientific, G.E. Healthcare, Aragen Bioscience, and Sartorius AG are a few of the notable companies operating in the global cell line development market profiled in this report.
RECENT HAPPENINGS IN THIS MARKET:
In collaboration with the National Institutes of Standards and Technology, the American Type Culture Collection announced the launch of a mouse cell line authentication service in October 2019.
Exosomes (extracellular vesicles) produced from human cells were launched by ATCC (US) in October 2019 as reference materials or standards for several research applications.
In January 2023, the original Beacon Select system for cell line development provided by Berkeley Lights, a life science products industry in 2017, is getting an updated version by the name Beacon SelectTM. The newer version has several additional features, like an optofluidic system, and sold 130 units worldwide.
In January 2023, aiming to create the Exelixis antibody-drug conjugate (ADC) program, two industry giants, Ajinomoto Co. and Exelixis, have signed a license agreement. The agreement was necessary as Ajinomoto Co.'s proprietary site-specific bioconjugation and linker technologies are specific to the company and are required for the success of the project.
In January 2023, Millipore aims to offer up to a 40% cut in process development time for significant Companies using its VIrus Express service through the introduction of VirusExpress 293 Adeno-Associated Virus Production Platform. The CDMO plans on expanding its business ventures through this latest discovery.
In January 2023, Asimov, a mammalian synthetic biology company, is signing a license agreement with CBM, the top CDMO in cell line development from the U.S., to develop its clonal HEK293 suspension cell line to produce viral vectors. The CDMO provides the company with a GMP-qualified cell line for clinical and pre-clinical manufacturing.
The global cell line development market size was valued at USD 5.92 billion in 2022.
Geographically, North American cell line development accounted for the largest share of the global market in 2022.
The global cell line development market is estimated to grow at a CAGR of 16.12% from 2023 to 2028.
Merck KGaA, Selexis SA, Lonza, ATCC, Solentim Ltd., Sphere Fluidics Limited, WuXi Biologics, Thermo Fisher Scientific, G.E. Healthcare, Aragen Bioscience, and Sartorius AG are some of the significant players operating in cell line development market
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2500
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: firstname.lastname@example.org